Synthesis and translational evaluation of three novel PARP PET tracers in nonhuman primates and rodent glioma brain tumor model with intact blood-brain barrier

IF 3.6 4区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Nuclear medicine and biology Pub Date : 2023-11-01 DOI:10.1016/j.nucmedbio.2023.108453

Jie Tong, Takuya Takuya, Monique A. Thomas, Mingming Chen, Daniel Holden, Stephen Kurpiewski, Samantha Katz, Baosheng Chen, William Mennie, Mike Wenn, Michael Kapinos, Li Zhang, Zachary Felchner, Hong Gao, David Labaree, Krista Fowles, Jim Ropchan, Nabeel Nabulsi, Henk De Feyter, Richard Carson, Jason Cai

引用次数: 0

查看原文本刊更多论文

三种新型PARP PET示踪剂的合成及在血脑屏障完好的非人灵长类和啮齿动物胶质瘤脑肿瘤模型中的转化评价

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nuclear medicine and biology 医学-核医学

CiteScore

6.00

自引率

9.70%

发文量

479

审稿时长

51 days

期刊介绍： Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis, in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized. These multidisciplinary studies should validate the mechanism of localization whether the probe is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the probe to changes in disease or treatment, although studies validating mechanism alone are acceptable. Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field. Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.